Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. GPA33, expressed on 95% of CRC, has been extensively targeted by IgG-attached payloads in conventional radioimmunotherapy (RIT), but toxicity was dose-limiting. A 2-step pretargeted radioimmunotherapy (PRIT) regimen using Self-Assembling-Disassembling antibody (SADA) specific for GPA33 (10 mg/kg) intravenous (IV) in step #1 and 24 h later [86Y]Y-ABD (9 nmole) IV in step #2, avoided normal gut uptake in non-human primates. Dosimetry results based on tissue counting in murine models using GPA33-SADA IV in step #1 and [225Ac]Ac-Pr in step #2, were 30.88, 0.1 and 2.56 Gy/uCi (Gy/37 kBq; RBE= 1), respectively for subcutaneous (sq) SW1222 tumor, blood and kidney, demonstrating favorable therapeutic ratios (309 for blood; 12 for kidney). Established sq SW1222 xenografts treated with 225Ac-SADA-PRIT showed dose dependent improvement in median survival (MS). Using one cycle of 2 doses 7 days apart (74kBq + 74kBq of 225Ac), majority of mice had complete tumor volumetric responses of sq SW1222, LS174T, LOVO and intraperitoneal SW1222 xenografts. Complete response was confirmed histologically at 180 days, accompanied by statistically significant improvements in MS. All treatments were well tolerated, with transient reversible weight loss (<15%), minimal hematologic, and no acute (within 30 days post 225Ac) chemical toxicities. At necropsy, kidneys showed minimal to marked subclinical tubular injury. The ability of a single cycle of 225Ac-SADA-PRIT to induce major CRC response and durable remission with minimal acute toxicities in multiple xenograft models while avoiding on-target off-tumor gut toxicity is encouraging, although subclinical histologic renal and ovarian damage remain a concern.
No takes yet. Share an insight, caveat, or question.
Aguirre et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: